PMID: 7522538Aug 1, 1994Paper

TP53 mutations are frequent in malignant NF1 tumors

Genes, Chromosomes & Cancer
E LegiusT W Glover

Abstract

Neurofibromatosis type I (NFI) is a common autosomal dominant disorder with an increased risk for developing benign and malignant tumors. The NFI gene has been cloned and maps to 17q11.2, and the gene product acts as a tumor suppressor gene. Here we analyzed the role of mutations in TP53 in four malignant NFI tumors. Mutations were found in 3 out of 4 tumors. One of these mutations is a common missense mutation in codon 278 in one of the previously identified hot spots for mutations. The two other are hitherto unreported mutations, including a splice mutation of exon 3 and a nonsense mutation in exon 4. In addition, these four tumors also showed loss of heterozygosity (LOH) for markers on chromosome 17 in the region of TP53. Malignant NFI tumors are initiated by a somatic inactivation of the second NFI allele. Tumor progression, however, occurs by accumulation of additional genetic abnormalities, such as homozygous inactivation of TP53, as demonstrated in this paper.

References

Jan 1, 1992·Genes, Chromosomes & Cancer·C Caron de Fromentel, T Soussi
Jul 5, 1991·Science·M HollsteinC C Harris
Jan 1, 1991·Genes, Chromosomes & Cancer·T W GloverS Johnson
Jul 11, 1991·Nucleic Acids Research·G F XuR White
Jul 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·A G MenonF P Li
Sep 1, 1988·The New England Journal of Medicine·B VogelsteinJ L Bos
Jan 1, 1986·Annual Review of Genetics·A G Knudson
Sep 11, 1993·Nucleic Acids Research·H DierickJ J Cassiman

❮ Previous
Next ❯

Citations

Dec 14, 2011·Acta Neuropathologica·Steven L Carroll
Jun 5, 2003·Cancer Genetics and Cytogenetics·Nadine Van RoyFrank Speleman
Jul 10, 2003·Cancer Genetics and Cytogenetics·Mary H HaddadinConstance A Griffin
Aug 25, 1999·Cancer Genetics and Cytogenetics·L KluweV F Mautner
Oct 20, 2009·Expert Reviews in Molecular Medicine·Daniela KatzDina Lev
Jan 24, 2006·Neuron Glia Biology·Philip R LeeR Douglas Fields
Nov 15, 2002·Clinical Genetics·T Tucker, J M Friedman
Oct 29, 2011·Journal of the National Cancer Institute·Eric PasmantUNKNOWN NF France Network
May 6, 2009·Molecular and Cellular Biology·Vidya BodempudiFaris Farassati
Dec 22, 1999·Journal of Clinical Pathology·J F Graadt van RoggenP C Hogendoorn
Dec 14, 2011·Human Genomics·Sebastian Laycock-van SpykMeena Upadhyaya
Jul 25, 2008·Neuro-oncology·Nikola HoltkampAndreas von Deimling
Nov 10, 2012·PloS One·Maren BradtmöllerNikola Holtkamp
Aug 21, 2007·Paediatric Drugs·Andrea FerrariModesto Carli
Jan 2, 2010·Neurosurgical Focus·Oren N GottfriedWilliam T Couldwell
Sep 26, 2002·Journal of Neurosurgery·Stacey A WoodsAbhijit Guha
May 13, 2014·Advances in Biological Regulation·Ophélia Maertens, Karen Cichowski
Jun 9, 1995·International Journal of Cancer. Journal International Du Cancer·F MertensN Mandahl
Dec 17, 2009·Journal of Neuropathology and Experimental Neurology·Robert M VerdijkJohan M Kros
Dec 14, 1999·The American Journal of Pathology·H P KoureaJ M Woodruff
May 17, 2014·The American Journal of Pathology·Eric P RahrmannDavid A Largaespada
May 5, 2009·The Lancet Oncology·Hilde BremsEric Legius
Nov 8, 2008·The American Journal of Pathology·Faris FarassatiAndreas Kurtz
Nov 5, 2003·Medical and Pediatric Oncology·Draga BarbaricLuciano Dalla-Pozza
Apr 29, 2008·American Journal of Medical Genetics. Part a·H StewartM Upadhyaya

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.